cck-a

CCK-A receptor inhibitor 1 是一种有效的缩胆囊素 A (CCK-A) 受体抑制剂(IC50：340 nM）。CCK-A receptor inhibitor 1 可用于研究与消化系统相关的疾病。

(Iso)-FK-480 是一种新型可口服的胆囊收缩素 A（CCK-A）拮抗剂，可用于研究治疗慢性胰腺炎。

Proglumide (Binoside) 是一种非肽的、口服具有活性的胆囊收缩素(CCK)-A/B 受体拮抗剂。它能够选择性阻断 CCK 在中枢神经系统中的作用。它能够抑制胃分泌，具有保护胃十二指肠粘膜的能力，并表现出抗癫痫和抗氧化活性。

Gastrin/CCK antagonist 1 是一种有效的 gastrin/CCK 拮抗剂，可用于研究代谢系统相关疾病。

CCK-B Receptor Antagonist 2 is a potent and orally active antagonist of Gastrin/CCK-B (IC50: 0.43 nM). It also inhibits gastrin/CCK-A activity (IC50: 1.82 μM).

Tarazepide is a potent and specific antagonist of CCK-A receptor.

Sograzepide (Netazepide) 是一种具有口服活性选择性和高效性的 Gastrin/CCK-B 拮抗剂，抑制 Gastrin/CCK-A 活性，抑制 1 型胃神经内分泌肿瘤中 Pappalysin 2 的表达，可诱导 1 型胃神经内分泌肿瘤消退。

PD-149164 is an agonist of the CCK-A receptor.

(Rac)-FK 480 可用于研究癫痫或焦虑症。

PD 135158 is a CCK2 receptor antagonist.

TP-680 is a antagonist of cholecystokininA receptor.

A-65186 是一种选择性A型谷氨酸基胆囊收缩素 （CCK） 拮抗剂，可用于研究炎症和胃肠道损伤。

Itriglumide (CR-2945) 是一种胆囊收缩素 （CCK）-2 受体拮抗剂，具有抗分泌和抗溃疡作用。

N-Cbz-DL-tryptophan 是一种胆囊收缩素受体拮抗剂，可消除离体心脏对 CCK-8 的反应。

Proglumide hemicalcium is a antagonist of nonpeptide and orally active cholecystokinin (CCK)-A/B receptors, has antiepileptic and antioxidant activities.

CCK-B Receptor Antagonist 1 is a cholecystokinin B (CCK-B) receptor agonist and has the potential of reducing the secretion of gastric acid.

Ceruletide Ammonium acetate (FI-6934 Ammonium acetate) 是一种胆囊收缩素 (CCK) 受体激动剂。它是一种安全有效的胆囊动力剂和小肠和胰腺外分泌兴奋剂。

Devazepide 是一种竞争性、选择性、可口服的非肽类CCK1(cholecystokinin 1)受体拮抗剂，能够抑制膀胱癌细胞增殖和迁移，诱导细胞凋亡和细胞周期阻滞。

Dexloxiglumide, an active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). It is a selective antagonist of cholecystokinin type A (CCKA) receptors.

YM022 is a highly effective and selective gastrin/cholecystokinin (CCK)-B receptor antagonist. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively.

Nastorazepide (Z-360) hemicalcium 作为一种1,5-苯二氮卓衍生物，是选择性的口服胃泌素/胆囊收缩素 2 (CCK-2) 受体拮抗剂，展现了潜在的抗肿瘤效果。

Cholecystokinin (27-32)-amide is a CCK receptor antagonist.

DA-3934 has a high affinity for gastrin/CCK-B receptors and high selectivity over CCK-A receptors. DA-3934 and its methyl ester derivative inhibited pentagastrin-induced gastric acid secretion in rats in a dose-dependent manner.

L 365031 is a CCK antagonist.